Binance founder Changpeng Zhao warned that artificial intelligence can harm Bitcoin users by enabling sophisticated phishing and social engineering attacks using leaked personal data, without needing to break Bitcoin's cryptographic protections. The FBI has also highlighted AI-assisted financial scams involving fake websites and impersonations. While Zhao suggested banks use weaker encryption than Bitcoin, this claim lacks detailed evidence. Past incidents like Coinbase's 2025 data breach and fake Ledger wallet phishing scams show how attackers exploit personal data to deceive users, but none involved breaking Bitcoin's cryptography. The risk lies in AI-enhanced deception rather than cryptographic vulnerabilities.
The Bitcoin security debate involving AI phishing provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 24, 2026 02:31 WIB: out of 50 priced assets, 36 rose and 13 fell. Notable moves include SAND at Rp938 with a 1-day change of -4.41% and a typical hold time of 124 days, COTI at Rp202 up 3.90% with 84% sell order activity, and VET at Rp130 up 3.33% with 88% sell order activity.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
